Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Rapid Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Quick Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Prompt Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Prompt Track designation for its C-Cure® therapy. The FDA granted Prompt Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Prompt Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Rapid Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to figure weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to figure weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Prompt Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to figure weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Quick Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Rapid Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Quick Track designation for its C-Cure® therapy. The FDA granted Prompt Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to figure weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Prompt Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Quick Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Quick Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Sustained progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to figure weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Prompt Track designation for its C-Cure® therapy. The FDA granted Prompt Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to bod weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Prompt Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Rapid Track designation for its C-Cure® therapy. The FDA granted Rapid Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Prompt Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to figure weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Prompt Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The utter interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Swift Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Constant progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to assets weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Prompt Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enlargened share of future revenues generated by these assets, including revenues from its sub-licensees.

In comeback, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Ultimately, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enlargened ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress – PM360

Celyad Reports Very first Half two thousand seventeen Financial Results and Operational Progress

Celyad’s management will host a conference call at 2pm CEST / 8am EDT today

• Strong progress in THINK trial with very first signals of clinical activity in solid tumors
• Non-exclusive license agreement signed with Novartis
• Fresh licensing agreement reached with CAR-T technology inventors
• Strong central IP position in the allogeneic CAR-T field confirmed by USPTO

MONT-SAINT-GUIBERT, Belgium, Aug. 29, two thousand seventeen (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced its consolidated financial results for the six-month period ending thirty June 2017, ready in accordance with IFRS as endorsed by the European Union. The total interim financial report is available on Celyad’s website in the Investors section. The half year two thousand seventeen consolidated financial statements were subject to a limited review by the company’s statutory auditors.

Operational Highlights of the very first half of 2017

Stable progress has been made in advancing the THINK trial (THerapeutic Immunotherapy with CAR-T NKG2D), Celyad’s 2nd clinical trial with its lead product candidate, CYAD-01 (CAR-T NKG2D).

The THINK trial was initiated in late two thousand sixteen and is being conducted in the United States and Europe. THINK includes two stages: a dose escalation and an extension stage. The dose escalation stage is being conducted in parallel in five solid cancers (colorectal, pancreatic, ovarian, triple negative breast and bladder) and in two hematologic cancer groups (Acute Myeloid Leukemia (AML) and Numerous Myeloma (MM), while the extension phase will evaluate in parallel each tumor type independently. The dose escalation design includes three dose levels adjusted to figure weight: up to 3×10 eight , 1×10 nine and 3×10 nine CYAD-01 cells. At each dose, the patients receive three successive administrations, two weeks apart, of CYAD-01 at the specified dose.

All patients enrolled in the 2nd cohort of the solid arm have been dosed successfully, as well as the very first patient enrolled in the 2nd cohort of the liquid arm. No adverse events have been reported.

Major clinical milestones achieved in the very first half of two thousand seventeen include:

• No adverse events reported in patients treated to date in both the solid and liquid arms, in-line with the positive safety profile seen in the CM-CS1 Phase I clinical trial conducted in two thousand fifteen and two thousand sixteen in the US. To date there have been no reports of safety concerns including unexpected serious adverse reactions, dose limiting toxicities or cytokine release syndrome toxicity;
• Promising early clinical results were reported at the 3-month follow-up from the very first dose-level in solid tumors. At the very first three x ten 8 cell dose-level administered to a total of three patients with metastatic cancer, the two colorectal cancer (mCRC) patients progressing after at least two prior chemotherapy regimens, achieved a confirmed Stable Disease according to RECIST criteria at three months.

In July, Celyad initiated the SHRINK trial (Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D), the third clinical trial with CYAD-01. SHRINK is an open-label Phase I trial evaluating the safety and clinical activity of numerous doses of CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer.

Dr. Christian Homsy, CEO of Celyad, said: “We are very pleased with these encouraging preliminary results from the THINK trial, with signs of clinical activity reported in colorectal cancer patients at the very first dose administered. With these early data, we feel even more encouraged about the clinical development plan of our lead program, CYAD-01, and look forward to quickly advancing the SHRINK trial. We hope to gather extra evidence of clinical activity in both hematological and solid tumor indications over the 2nd half of 2017.”

In May, Celyad announced that the U.S. Food and Drug Administration (FDA) had granted Swift Track designation for its C-Cure® therapy. The FDA granted Quick Track Development Program designation based on CHART-1 data related to reduction in mortality, hospitalization and improvement of quality of life in patients with chronic heart failure secondary to ischemic cardiomyopathy with baseline Left Ventricular End-Diastolic Volumes (LVEDV) inbetween two hundred and 370ml.

In January, the U.S. Patent and Trade Office (USPTO) upheld, for a third time, Celyad’s U.S. Patent No. 9,181,527 relating to allogeneic human primary T-cells that are engineered to be TCR-deficient and express a chimeric antigen receptor (CAR). In March, the USPTO rejected another request for a re-examination of the same patent. Celyad’s critical patent remains valid and enforceable.

In May, Celyad obtained a fresh patent related to its method of treating cancer by administering allogeneic primary human T cells that are engineered to be T-Cell Receptor (TCR)-deficient and to express a CAR. US Patent No. 9,663,763 is the third patent in Celyad’s allogeneic intellectual property portfolio awarded by the USPTO. This fresh patent claims specifically methods of treating cancer patients with allogeneic TCR-deficient CAR-T immunotherapies. Earlier patents were related to the allogeneic TCR-deficient CAR-T cells per se, and to methods of producing them. The combination of this patent with earlier granted US patents consolidates Celyad’s strong intellectual property (IP) position in the allogeneic CAR-T field and strengthens the Celyad’s IP portfolio covering key elements in the allogeneic TCR-deficient CAR-T cells production value chain.

In May, Celyad announced a non-exclusive license agreement with Novartis regarding US patents related to allogeneic CAR-T cells. The agreement includes Celyad’s intellectual property rights under U.S. Patent No. 9,181,527 related to allogeneic human primary T-Cells engineered to be TCR deficient and express a CAR. This agreement is related to two undisclosed targets presently under development by Novartis.

Under the terms of the agreement, Celyad received an upfront payment and is eligible to receive success-based clinical, regulatory and commercial milestone payments in aggregate amounts of up to $96 million. In addition, Celyad is eligible to receive royalties based on net sales of the licensed target associated products at percentages in the single digits. Celyad retains all rights to grant further licenses to third parties for the use of allogeneic CAR-T cells.

In August 2017, Celyad amended its agreements with Celdara Medical LLC and Dartmouth College related to the CAR-T NK cell drug product candidates and related technology licensed in January two thousand fifteen following the acquisition of OnCyte LLC. Under the amended agreements Celyad is to receive an enhanced share of future revenues generated by these assets, including revenues from its sub-licensees.

In come back, Celyad paid Celdara Medical LLC and Dartmouth College an upfront payment of $12.Five million (€10.6 million) and issued to Celdara Medical LLC $12.Five million worth of Celyad’s ordinary shares at a share price of €32.35. The financial effects of the above transactions have not been brought to account in the interim consolidated financial statements of Celyad as of thirty June two thousand seventeen and may materially influence Celyad’s income statement in the consolidated financial statements at year end 2017.

Dr. Christian Homsy, CEO of Celyad, continued: “The non-exclusive license agreement contracted with Novartis serves as a key validation of our central intellectual property position in the allogeneic CAR-T field. Eventually, the fresh terms negotiated with Celdara Medical and Dartmouth College should help provide long-term value to Celyad’s shareholders, while the enhanced ownership of Celdara Medical in Celyad signals a commitment to our development of promising CAR-T cell therapies.”

Patrick Jeanmart, Chief Financial Officer of Celyad, commented: “Cash and resource management of our group remains a key concentrate for Celyad, and this effort has permitted us to meaningfully advance the preclinical and clinical development of our promising CAR-T platform across numerous significant indications. We ended the very first half of two thousand seventeen with €69 million in cash and short-term deposits which we believe is sufficient to support operating expenses and capital expenditure requirements, based on the current scope of our activities, through the very first half of 2019.”

Selected Very first Half two thousand seventeen Financial Results

Related movie: